Yeast cell wall polysaccharides as antioxidants and antimutagens: Can they fight cancer?

Neoplasma

Volumn 55, Issue 5, 2008, Pages 387-393

  Kogan, G ^a,d   Pajtinka, M ^a   Babincova, M ^b   Miadokova, E ^b   Rauko, P ^a   Slamenova, D ^a   Korolenko, T A ^c  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^d EUROPEAN COMMISSION   (Belgium)

Author keywords

Anticancer; Antimutagen; Antioxidant; Glucan; Glucomannan; Yeast polysaccharide

Indexed keywords

(1-3) BETA DEXTRO GLUCAN; ALPHA GLUCAN; ANTIMUTAGENIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BETA DEXTRO GLUCAN; CYCLOPHOSPHAMIDE; MANNAN; POLYSACCHARIDE; TENIPOSIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; (1 6) ALPHA GLUCOMANNAN; (1-6)-ALPHA-GLUCOMANNAN; BETA GLUCAN; FUNGAL PROTEIN; SACCHAROMYCES CEREVISIAE PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANDIDA UTILIS; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG POTENTIATION; ELECTRON SPIN RESONANCE; GENOTOXICITY; LIPID PEROXIDATION; LUNG CARCINOMA; LYMPHOSARCOMA; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PROTEIN SECRETION; SACCHAROMYCES CEREVISIAE; YEAST CELL; ANIMAL; CANDIDA; CELL WALL; CHEMISTRY; CHEMOPROPHYLAXIS; HUMAN; NEOPLASM; REVIEW; YEAST;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIMUTAGENIC AGENTS; ANTIOXIDANTS; BETA-GLUCANS; CANDIDA; CELL WALL; CHEMOPREVENTION; FUNGAL PROTEINS; HUMANS; MANNANS; NEOPLASMS; POLYSACCHARIDES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; YEASTS;

EID: 53449094701     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. De FLORA S, FERGUSON LR. Overview of mechanisms of cancer chemopreventive agents. Mutat Res, Fundam Mol Mech Mutagen 2005; 591:8-15. (Pubitemid 41654835)
2. De FLORA S, BALANSKY R, SCATOLINI L et al. Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention. In: Stewart BW, McGregor D, Kleihues P, editors. Principles of chemoprevention, Lyon: IARC Sci. Publ. No.139, International Agency for Research on Cancer, 1996: 291-301.
3. D'AGOSTINI F, BAGNASCO M, GIUNCIUGLIO D et al. Inhibition by oral N-acetylcysteine of doxorubicin induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol 1998; 13: 217-224.
4. WASSER SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002; 60: 258-274. (Pubitemid 35352092)
5. BORCHERS AT, KEEN CL, GERSHWIN ME. Mushrooms, tumors, and immunity: An update. Exp Biol Med 2004; 229: 393-406.
6. FARKAŠ V. Biosynthesis of cell walls of fungi. Microbiol Rev 1979; 43: 117-144.
7. BARTNICKI-GARCIA S. Cell wall chemistry, morphogenesis, and taxonomy of fungi. Annu Rev Microbiol 1968; 22: 87-108.
8. CABIB E. Carbohydrates as structural constituents of yeast cell wall and septum. Pure Appl Chem 1991; 63: 483-489.
9. CABIB E, ROH D-H, SCHMIDT M et al. The yeast cell wall and septum as paradigms of cell growth and morphogenesis. J Biol Chem 2001; 276: 19679-19682. (Pubitemid 37411023)
10. BALLOU CE. Structure and biosynthesis of the mannan component of the yeast cell wall envelope. Adv Microbiol Physiol 1976; 14: 93-158.
11. DOMER JE. Candida cell wall mannan: a polysaccharide with diverse immunologic properties. Crit Rev Microbiol 1989; 17: 33-51.
12. KOGAN G, PAVLIAK V, ŠANDULA J et al. Structure of the cell wall of mannans of the pathogenic yeasts of Candida species - a complex insight. Carbohydr Polym 1991; 14: 65-76.
13. SCHREUDER MP, MOOREN ATA, TOSCHKA HY et al. Immobilizing proteins on the surface of yeast cells. Trends Biotechnol 1996; 14: 115-120. (Pubitemid 26127524)
14. TSIAPALI E, WHALEY S, KALBFLEISCH J et al. Glucans exhibit weak antioxidant activity, but stimulate macrophage free radical activity. Free Radical Biol Med 2001; 30: 393-402.
15. KRIŽKOVÁ L, ĎURAČKOVÁ Z, ŠANDULA J et al. Antioxidative and antimutagenic activity of yeast cell wall mannans in vitro. Mutat Res, Genet Toxicol Environ Mutagen 2001; 497: 213-222.
16. WILLCOX JK, ASH SL, CATIGNANI GL. Antioxidants and prevention of chronic diseases. Crit Rev Food Sci Nutr 2004; 44: 275-295.
17. HALLIWELL B. Free radicals and antioxidants: A personal view. Nutr Rev 1994; 52: 253-265. (Pubitemid 24308025)
18. BOBEK P, OZDIN L, KUNIAK L. Effect of oyster mushroom and isolated beta-glucan on lipid peroxidation and on the activities of antioxidative enzymes in rats fed on cholesterol diet. J Nutr Biochem 1997; 8: 469-471.
19. XIE W, XU P, LIU Q. Antioxidant activity of water-soluble chitosan derivatives. Bioorg Med Chem Lett 2001; 11:1699-1701. (Pubitemid 32568301)
20. KLEIN RA. The detection of oxidation in liposome preparations. Biochim Biophys Acta 1970; 210: 486-489.
21. BABINCOVÁ M, MACHOVÁ E, KOGAN G. Carboxymethylated glucan inhibits lipid peroxidation in liposomes. Z Naturforsch 1999; 54c: 1084-1088.
22. BABINCOVÁ M, BAČOVÁ Z, MACHOVÁ E et al. Antioxidant activity of carboxymethyl glucan: Comparative analysis. J Med Food 2002; 5: 79-83.
23. SCHORNEROVÁ K, BABINCOVÁ M, MACHOVÁ E et al. Carboxymethylated (1→3)-β-D-glucan protects liposomes against ultraviolet light induced lipid peroxidation. J Med Food 2007; 10: 189-193.
24. KOGAN G, STAŠKO A, BAUEROVÁ K et al. Antioxidant properties of yeast (1→3)-β-D-glucan studied by Electron Paramagnetic Resonance spectroscopy and its activity in the adjuvant arthritis. Carbohydr Polym 2005; 61: 18-28.
25. SLAMEŇOVÁ D, LÁBAJ J, KRIŽKOVÁ L et al. Protective effects of fungal (1→3)-β-D-glucan derivatives against oxidative DNA lesions in V79 hamster lung cells. Cancer Lett 2003; 198: 153-160.
26. IVANOVA T, HAN Y, SON H-J et al. Antimutagenic effect of polysaccharide ginsan extracted from Panax ginseng. Food Chem Toxicol 2006; 44: 517-521.
27. SHON Y-H, NAM K-S. Antimutagenicity and induction of anticarcinogenic phase II enzymes by basidiomycetes. J Ethnopharmacol 2001; 77: 103-109. (Pubitemid 32727752)
28. OHE T. Antigenotoxic activities of chitin and chitosan as assayed by sister chromatid exchange. Sci Total Environ 1996; 181: 1-5.
29. KOGAN G, SKORIK YA, ŽITŇANOVÁ I et al. Antioxidant and antimutagenic activity of N-(2-carboxyethyl)chitosan. Toxicol Appl Pharmacol 2004; 201: 303-310.
30. CHORVATOVIČOVÁ D, KOVÁČIKOVÁ Z, ŠANDULA J et al. Protective effect of sulfoethylglucan against hexavalent chromium. Mutat Res Lett 1993; 302: 207-211. (Pubitemid 23236598)
31. CHORVATOVIČOVÁ D, MACHOVÁ E, ŠANDULA J. Effect of ultrasonicated carboxymethylglucan on cyclophosphamide induced mutagenicity. Mutat Res, Genet Toxicol 1996; 371: 115-120. (Pubitemid 26386344)
32. CHORVATOVIČOVÁ, D, MACHOVÁ E, ŠANDULA J et al. Protective effect of the yeast glucomannan against cyclophosphamide- induced mutagenicity. Mutat Res, Genet Toxicol Environ Mutagen 1999; 444: 117-122. (Pubitemid 29341530)
33. SCHIMMEL KJ, RICHEL DJ, VAN DEN BRINK RB et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181-191.
34. KUMAR KB, KUTTAN R. Chemoprotective activity of an extract of Phyllanthus amarus against cyclophosphamide induced toxicity in mice. Phytomedicine 2005; 12: 494-500.
35. MIADOKOVÁ E, SVIDOVÁ S, VLČKOVÁ V et al. The role of microbial polysaccharides in cancer prevention and therapy. J Cancer Integr Med 2004; 2: 173-178.
36. VLČKOVÁ V, DÚHOVÁ V, SVIDOVÁ S et al. Antigenotoxic potential of glucomannan on four model test systems. Cell Biol Toxicol 2004; 20: 325-332.
37. MIADOKOVÁ E, SVIDOVÁ S, VLČKOVÁ V et al. Diverse biomodulatory effects of glucomannan from Candida utilis. Toxicol in Vitro 2006; 20: 649-657.
38. KRIŽKOVÁ L, ĎURAČKOVÁ Z, ŠANDULA J et al. Fungal β-(1-3)-D-glucan derivatives exhibit high antioxidative and antimutagenic activity in vitro. Anticancer Res 2003; 23: 2751-2756.
39. TREBATICKÁ M, SVIDOVÁ S, GROLMUS J et al. Sulphoethyl glucan - a biological active polysaccharide. Biologia 2005; 60/Suppl. 17: 119-121.
40. KOGAN G, ŠANDULA J, KOROLENKO TA et al. Increased efficiency of Lewis lung carcinoma chemotherapy with a macrophage stimulator - yeast carboxymethyl glucan. Int Immunopharmacol 2002; 2: 775-781.
41. KHALIKOVA TA, ZHANAEVA SYA, KOROLENKO TA et al. Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide. Cancer Lett 2005; 223: 77-83.
42. KHALIKOVA TA, KOROLENKO TA, ZHANAEVA SYA et al. Enhancing effect of new biological response modifier sulfoethylated (1→3)-β-D-glucan on antitumor activity of cyclophosphamide in the treatment of experimental murine leukoses. Exp Oncol 2006; 28: 308-313.
43. RAUKO P, BAUER W, HORVÁTH Z et al. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro in mice. Anticancer Res 2003; 23: 3841-3846.
44. THORNTON BP, VETVICKA V, PITMAN M et al. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996; 156: 1235-1246. (Pubitemid 26048122)
45. VETVICKA V, THORNTON BP, ROSS GD. Soluble β- glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 1996; 98: 50-57.
46. ROSS GD, CAIN JA, MYONES BL et al. Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement 1987; 4: 61-74.
47. ZIMMERMAN JW, LINDERMUTH J, FISH PA et al. A novel carbohydrate- glycosphingolipid interaction between a beta-(1-3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J Biol Chem 1998; 273: 22014-22020.
48. RICE PJ, KELLEY JL, KOGAN G et al. Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-β-D-glucans. J Leukocyte Biol 2002; 72: 140-146.
49. BROWN GD, GORDON S. Immune recognition: a new receptor for beta-glucans. Nature 2001; 413: 36-37.
50. MAJTÁN J, KOGAN G, KOVÁČOVÁ E et al. Stimulation of TNF-α release by fungal cell wall polysaccharides. Z Naturforsch 2005; 60c: 921-926.
51. OOI VE, LIU F. Immunomodulation and anticancer activity of polysaccharide-protein complexes. Curr Med Chem 2000; 7: 715-729.
52. KOGAN G. (1→3,1→6)-β-D-Glucans of yeasts and fungi and their biological activity. In: Atta-ur-Rahman, editor. Studies in natural products chemistry. Bioactive Natural Products (Part D), Vol.23, Amsterdam: Elsevier, 2000: 107-152.
53. KIDD PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000; 5: 4-27. (Pubitemid 30132069)
54. ZAIDMAN B-Z, YASSIN M, MAHAJNA J et al. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 2005; 67: 453-468.
55. MORADALI M-F, MOSTAFAVI H, GHODS S et al. Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int Immunopharmacol 2007; 7: 701-724.
56. ZHANG M, CUI SW, CHEUNG PCK et al. Antitumor polysaccharides from mushrooms: a review on their isolation process, structural characteristics and antitumor activity. Trends Food Sci Technol 2007; 18: 4-19.